Project Grant HT9425261E114
Award Date 5/1/26
Completion Date 4/30/30
Dollars Obligated $800K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90024, USA
Similar Awards
- Federal Grant Award Summary The University of California, Los Angeles (UCLA) received a $1,698,858 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective June 1, 2026, through May 31, 2029. The award supports research focused on "The 3D Multiomic Determinants of Prostate Cancer Lethality," with research to be conducted at UCLA's Los Angeles, California campus. This project represents a hypothesis-driven...
- This federal Project Grant award, valued at $2,520,000.00, was issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The primary awardee, the University of California, Los Angeles (UCLA), will leverage its extensive facilities, diverse faculty expertise, and robust administrative capabilities...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded a $235,476 project grant to the University of California, Los Angeles (UCLA) Office of Research Administration on November 1, 2025, to develop new cell-mediated immunotherapeutic strategies for neuroendocrine prostate cancer. The two-year award, which concludes October 31, 2027, is funded under the Military Medical Research and Development program (CFDA 12.420) and will be conducted at UCLA's Los Angeles, California facility....
- Federal Grant Award Summary The University of California, Los Angeles (UCLA) received a $551,216 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective August 1, 2025, through July 31, 2027. The grant funds research to elucidate the functional role of PPP1R1B-lncRNA in myocyte repair in Duchenne muscular dystrophy (DMD). This research initiative represents a hypothesis-driven investigation into therapeutic...
- Federal Project Grant Award Summary The Defense Health Agency (DHA), through its Military Medical Research and Development program (CFDA 12.420), awarded a $157,500 Project Grant to the University of California, Los Angeles (UCLA) Office of Research Administration, effective September 1, 2025, with completion scheduled for August 31, 2026. The award supports research investigating the impact of a hypomorphic SMARCB1 germline allele specific for schwannomatosis on mouse development and...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded UCLA a $350,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to develop a polylactic acid (PLA)-based, immunohistochemistry (IHC)-compatible functional assay for detecting homologous recombination deficiency in ovarian cancer. The award, issued on September 30, 2026, with a completion date of September 29, 2028, supports translational research to advance diagnostic capabilities for...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded UCLA a $2.16M Project Grant on September 30, 2025, under the Military Medical Research and Development program (CFDA 12.420) to conduct research on cerebellar neuromodulation to reduce cognitive dysfunction after multiple subconcussive impacts. The four-year project, scheduled for completion on September 29, 2029, will be performed at UCLA's Los Angeles campus through the Office of Research Administration. This award supports...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded the University of California, Los Angeles (UCLA) a $590,625 project grant effective September 1, 2025, through August 31, 2028, under the Military Medical Research and Development program (CFDA 12.420). The grant funds a pilot study investigating dual immunotherapy targeting PD-1 (programmed death receptor 1) and CD73 in combination with chemotherapy for patients with pancreatic adenocarcinoma, with specific focus on...
- Federal Grant Award Summary UCLA has received a $2.08M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2026 through August 31, 2030. The grant supports research to define an error-free DNA repair signature as a predictive marker for lethal prostate cancer. This research initiative contributes to the DHA's broader mission of advancing biomedical innovation to transform healthcare for military...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded University of California, Los Angeles (UCLA) a $590,625 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2028. UCLA will conduct a pilot study investigating dual immunotherapy targeting PD-1 (programmed death receptor 1) and CD73 in combination with chemotherapy for patients with pancreatic adenocarcinoma, with a focus on identifying immune...